of nicardipine (17 g/kg/min), irbesartan (430 g/kg/min), or nicardipine (17 g/kg/min) preceded by a small dose of irbesartan (600 g/kg). These doses were selected to produce a similar 20 mmHg reduction in mean arterial pressure (MAP) over 30 min. Changes in LSNA during drug-induced decreases in MAP were:
Sustained sympathetic activation induces left ventricular hypertrophy, smooth muscle cell hyperplasia, and may predispose to sudden death. We recently published that the calcium channel blocker nicardipine induces greater increases in lumbar sympathetic nerve activity (LSNA) and heart rate (HR) in spontaneously hypertensive rats (SHR) than the ACE inhibitor enalaprilat. The present study tested whether this effect is attributable to greater baroreceptor unloading. Recording electrodes were secured to the lumbar nerve of 9-wk old male SHR. Twenty-four hours later in conscious rats, LSNA was recorded during infusion of phenylephrine (10 -21 g/kg/min) sufficient to raise MAP by 20 mmHg followed by nicardipine (6 -12 g/kg/min) or enalaprilat (8 -12 g/kg) sufficient to lower MAP back to baseline. Phenylephrine-induced increase in MAP suppressed LSNA by 47%. Changes in LSNA during nicardipine or enalaprilat-induced reductions in MAP were:
These results indicate that nicardipine has a direct sympathoexcitatory effect independent of any change in MAP or right atrial pressure. In contrast, enalaprilat has a sympathoinhibitory effect. These contrasting effects on sympathetic activation may have differential effects on long-term cardiovascular risk. 
